Back to Search
Start Over
New signalling pathway involved in the anti-proliferative action of vitamin D₃ and its analogues in human neuroblastoma cells. A role for ceramide kinase.
- Source :
-
Neuropharmacology [Neuropharmacology] 2012 Sep; Vol. 63 (4), pp. 524-37. Date of Electronic Publication: 2012 May 08. - Publication Year :
- 2012
-
Abstract
- 1α,25-Dihydroxyvitamin D3 (1,25(OH)₂D₃), a crucial regulator of calcium/phosphorus homeostasis, has important physiological effects on growth and differentiation in a variety of malignant and non-malignant cells. Synthetic structural hormone analogues, with lower hypercalcemic side effects, are currently under clinical investigation. Sphingolipids appear to be crucial bioactive factors in the control of the cell fate: the phosphorylated forms, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P), are mitogenic factors, whereas sphingosine and ceramide (Cer) usually act as pro-apoptotic agents. Although many studies correlate S1P function to impaired cell growth, the relevance of C1P/Cer system and its involvement in neuroblastoma cells remain to be clarified. Here, we demonstrated the anti-proliferative effect of 1,25(OH)₂D₃ as well as of its structural analogues, ZK156979 and ZK191784, in human SH-SY5Y cells, as judged by [³H]thymidine incorporation, cell growth and evaluation of active ERK1/2 levels. The inhibition of ceramide kinase (CerK), the enzyme responsible for C1P synthesis, by specific gene silencing or pharmacological inhibition, drastically reduced cell proliferation. 1,25(OH)₂D₃ and ZK191784 treatment induced a significant decrease in CerK expression and C1P content, and an increase of Cer. Notably, the treatment of SH-SY5Y cells with ZK159222, antagonist of 1,25(OH)₂D₃ receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevented the decrease of CerK expression elicited by 1,25(OH)₂D₃ supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in CerK regulation. Altogether, these findings provide the first evidence that CerK/C1P axis acts as molecular effector of the anti-proliferative action of 1,25(OH)₂D₃ and its analogues, thereby representing a new possible target for anti-cancer therapy of human neuroblastoma.<br /> (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Subjects :
- Antineoplastic Agents antagonists & inhibitors
Calcitriol analogs & derivatives
Calcitriol antagonists & inhibitors
Calcitriol pharmacology
Cell Line, Tumor
Cell Survival drug effects
Ceramides metabolism
Enzyme Inhibitors pharmacology
Gene Silencing
Histone Deacetylase Inhibitors pharmacology
Humans
Molecular Targeted Therapy
Neoplasm Proteins antagonists & inhibitors
Neoplasm Proteins genetics
Neoplasm Proteins metabolism
Neuroblastoma drug therapy
Neuroblastoma enzymology
Phosphotransferases (Alcohol Group Acceptor) antagonists & inhibitors
Phosphotransferases (Alcohol Group Acceptor) genetics
RNA, Small Interfering
Receptors, Calcitriol antagonists & inhibitors
Vitamin D analogs & derivatives
Vitamin D pharmacology
Antineoplastic Agents pharmacology
Calcitriol metabolism
Cell Proliferation drug effects
Drugs, Investigational pharmacology
Neuroblastoma metabolism
Phosphotransferases (Alcohol Group Acceptor) metabolism
Signal Transduction drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1873-7064
- Volume :
- 63
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Neuropharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 22579669
- Full Text :
- https://doi.org/10.1016/j.neuropharm.2012.04.026